Bloomberg Intelligence’s Sam Fazeli discusses AbbVie’s $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie’s presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on “Bloomberg Open Interest.” (Source: Bloomberg)
Trending
- Reimagining Visionary Representation for Awka North and Awka South Federal Constituency – THISDAYLIVE
- Shootout Suspect Is Dead After Killing Montreal Police Officer, Authorities Say
- Keir Starmer Resigns as UK Prime Minister
- Amazon Prime Day arrives earlier this year. Here’s why Wall Street is watching closely
- Polymarket’s viral videos showed people winning big, but the bets were fake
- Amaechi’s Volte-face over Vice Presidential Ticket – THISDAYLIVE
- JOF U-13 Cup reaches grand finale in Lagos
- Free 2026 World Cup anytime goalscorer picks, odds, best bets: Mbappe, Haaland among best bets for Monday
